Compare SWBI & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | IRWD |
|---|---|---|
| Founded | 1852 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 658.5M |
| IPO Year | 2000 | 2009 |
| Metric | SWBI | IRWD |
|---|---|---|
| Price | $15.01 | $3.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $7.67 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 06-17-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | 36.67 | ★ 1400.00 |
| EPS | ★ 0.41 | 0.24 |
| Revenue | ★ $523,845,000.00 | $298,276,000.00 |
| Revenue This Year | $7.61 | $57.95 |
| Revenue Next Year | $3.72 | $4.39 |
| P/E Ratio | $36.24 | ★ $16.15 |
| Revenue Growth | ★ 10.36 | 8.88 |
| 52 Week Low | $7.73 | $0.72 |
| 52 Week High | $17.56 | $5.78 |
| Indicator | SWBI | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 44.78 |
| Support Level | $13.83 | $3.80 |
| Resistance Level | $15.24 | $3.95 |
| Average True Range (ATR) | 0.47 | 0.22 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 13.28 | 5.64 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.